SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue slipped marginally during the June 2023 quarter. A decline of about Rs. 105.81 millions was observed as compared to Rs. 106.41 millions during the corresponding quarter last year.The Net Loss for the quarter ended June 2023 is Rs. -53.32 millions as compared to Net Loss of Rs. -81.36 millions of corresponding quarter ended June 2022 Operating profit Margin for the quarter ended June 2023 improved to -25.82% as compared to -61.39% of corresponding quarter ended June 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202306 202206 % Var 202306 202206 % Var 202303 202203 % Var
Sales 105.81 106.41 -0.56 105.81 106.41 -0.56 521.34 597.03 -12.68
Other Income 0.38 1.29 -70.54 0.38 1.29 -70.54 6.20 11.56 -46.37
PBIDT -25.82 -61.39 -57.94 -25.82 -61.39 -57.94 -151.59 -328.39 -53.84
Interest 10.97 3.04 260.86 10.97 3.04 260.86 29.73 53.91 -44.85
PBDT -36.79 -64.43 -42.90 -36.79 -64.43 -42.90 -181.32 -382.30 -52.57
Depreciation 16.53 16.93 -2.36 16.53 16.93 -2.36 65.59 62.97 4.16
PBT -53.32 -81.36 -34.46 -53.32 -81.36 -34.46 -246.91 -445.27 -44.55
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -53.32 -81.36 -34.46 -53.32 -81.36 -34.46 -246.91 -445.27 -44.55
Equity 215.61 215.61 0.00 215.61 215.61 0.00 215.61 215.61 0.00
PBIDTM(%) -24.40 -57.69 -57.70 -24.40 -57.69 -57.70 -29.08 -55.00 -47.14

Krebs Biochem.&Inds Share Price

60.90 -0.12 (-0.20%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×